CD8A and neoplasm: Preclinical models have shown that targeting the tumor-draining lymphatics attenuates the response to ICB by reducing CD8+ T cell chemoattractant chemokine signaling and type I IFN signaling, and also reducing the expansion of antigen-experienced T cells and type I DCs in the draining nodes (Darragh et al., 2022a; Marciscano et al., 2018; Saddawi-Konefka et al., 2022).